Stacey M Frumm - JoVE Visualize

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

The Journal of Clinical Investigation|February 14, 2012

The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemiaVersha Banerji, Stacey M Frumm, Kenneth N Ross, et al.

Blood Advances|January 26, 2026

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic TransplantationLuis E Aguirre, Haesook T Kim, Hany Elmariah, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026

Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobaccoEleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.

Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

The Journal of Clinical Investigation|February 14, 2012

The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemiaVersha Banerji, Stacey M Frumm, Kenneth N Ross, et al.

Blood Advances|January 26, 2026

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic TransplantationLuis E Aguirre, Haesook T Kim, Hany Elmariah, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026

Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobaccoEleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.

Pageof 2